Tracking Cathie Wood: Increased position in blood safety company Cerus by over 450,000 shares; significantly reduced holdings in Roblox and biotech sectors

On Monday (August 17), the three major US stock indices closed lower collectively. The S&P 500 fell 0.52% to 7,745.06 points, the Nasdaq dropped 0.32% to 26,644.91 points, and the Dow Jones declined 0.51% to 53,459.78 points. Overall market sentiment remained cautious, with pressure on technology and growth stocks.

Against this backdrop, Cathie Wood took advantage of the market pullback to selectively increase positions in core sectors such as healthcare innovation, AI infrastructure, fintech, and blockchain. Simultaneously, she trimmed positions in targets that had already seen significant gains or whose investment thesis had weakened at the margin, demonstrating her consistent strategy of "shedding weak holdings while keeping strong ones" and precise allocation.

Buy Direction: Increase exposure to core innovation sectors during dips; cast a wide net to allocate into disruptive technologies

$Cerus (CERS.US)$ Record daily buying volume reached 451,278 shares. Cerus focuses on blood safety and pathogen inactivation technologies. Its INTERCEPT Blood System has established significant competitive barriers in the global blood transfusion safety sector. ARK may be bullish on its long-term potential in healthcare infrastructure transformation, increasing its position during the market correction.

$Block (XYZ.US)$ Increased holdings by 191,671 shares. Block’s Cash App and Spiral continue to advance the integration of the Bitcoin payment ecosystem. Amid the trend toward cryptocurrency compliance, ARK may believe that the underlying logic driven by both fintech and blockchain is strengthening. Adding positions at this time could offer a balanced offensive and defensive strategy.

$Securitize (SECZ.US)$ Purchased 189,796 shares. Securitize is a leading platform for the issuance and management of tokenized assets (RWA). As the trend of bringing traditional financial assets on-chain accelerates, ARK’s increased stake may reflect its continued optimism about the next-generation financial infrastructure赛道 focused on the tokenization of real-world assets.

$Freenome (FRNM.US)$ Increased holdings by 144,595 shares. Freenome is dedicated to early cancer screening through multi-omics liquid biopsy, aligning with ARK’s core investment theme of precision medicine. ARK may have chosen to add to its position at a critical juncture in the commercialization process of its products.

$NVIDIA (NVDA.US)$ Purchased 101,356 shares. As the absolute core of AI computing infrastructure, NVIDIA saw counter-trend buying from ARK during the broader market pullback. This may reflect ARK’s high confidence in the long-term demand prosperity of AI, viewing the correction as a rare entry opportunity.

$Nu Holdings (NU.US)$ Increased holdings by 51,473 shares. Nu Holdings is the largest digital finance platform in Latin America. Its vast untapped market and continuously growing user base constitute its core moat. ARK’s increase in holdings may indicate optimism about its continued expansion in financial inclusion within emerging markets.

$Tempus AI (TEM.US)$ Purchased 22,666 shares. Tempus AI combines clinical data with artificial intelligence to drive the implementation of precision medicine, highly aligning with ARK’s theme of AI-enabled healthcare. Continued accumulation may represent ARK’s long-term bullishness on its data flywheel effect.

$Scribe Therapeutics (SCTX.US)$ Increased holdings by 15,823 shares. Scribe focuses on the development of CRISPR-Cas, the next-generation gene-editing tool, positioning itself at the forefront of genetic engineering technology. ARK’s continued allocation may reflect its anticipation of an accelerated commercialization process for gene editing.

3iQ Solana Staking ETF (SOLQ.U.US): Purchased 7,115 shares. By increasing its stake in the Solana staking ETF, ARK further deepens its exposure to the Solana ecosystem, possibly believing that Solana’s high-throughput public chain has continuous explosive potential in DeFi and Web3 application layers.

$Ionis Pharmaceuticals (IONS.US)$ Increased holdings by 6,839 shares. Ionis is a pioneer in antisense oligonucleotide (ASO) technology, with a rich pipeline in neurological diseases and rare disorders. ARK’s increased holdings may indicate optimism about the commercial conversion prospects of its differentiated technology platform.

$Cloudflare (NET.US)$ Bought 5,001 shares. Cloudflare continues to expand in AI security, edge computing, and network infrastructure. ARK's small addition may be aimed at refining its technology infrastructure portfolio allocation during the broader market correction.

Sell-side activity: Primarily driven by position rebalancing, with dynamic allocation adjustments for certain holdings.

$Roblox (RBLX.US)$ Reduced by 592,227 shares, making it the largest sell-off of the day. As a metaverse concept stock, Roblox faces ongoing market skepticism regarding its user monetization efficiency and profitability. ARK's significant reduction may reflect a dynamic reallocation of resources within the metaverse sector, redirecting capital toward AI and healthcare innovation with greater certainty.

$AtaiBeckley (ATAI.US)$ Reduced by 226,381 shares. ATAI Life Sciences focuses on novel therapies for mental health, but faces high uncertainty in clinical progress. ARK's reduction may be aimed at trimming this position to optimize the risk-return profile of the overall portfolio.

$Shopify (SHOP.US)$ Reduced by 105,530 shares. Shopify's stock price has shown relative strength recently. ARK's adjustment may be to partially lock in profits and rebalance capital to support other emerging innovative targets with greater valuation elasticity.

$10x Genomics (TXG.US)$ Sold 94,968 shares. 10x Genomics holds a technological lead in spatial genomics, but its commercialization pace has slowed. ARK may have chosen to moderately reduce concentration in this holding to optimize the portfolio structure.

$Twist Bioscience (TWST.US)$ Reduced by 63,297 shares. Twist Bioscience has a unique positioning in DNA synthesis for synthetic biology. This reduction may represent ARK's overall rebalancing of allocations within the life sciences tools sector.

$Advanced Micro Devices (AMD.US)$ Sold 25,917 shares. AMD faces pressure in the AI accelerator race amid competition with NVIDIA. ARK may have moderately lowered its AMD weighting while adding to NVDA on the same day, reflecting a shift in preference within the AI computing power sector.

$Palantir (PLTR.US)$ Reduced by 22,023 shares. Palantir's valuation has become quite full recently. ARK's moderate adjustment may be an active management move to control position concentration and avoid excessive exposure to a single AI data analytics target.

$Natera (NTRA.US)$ Sold 20,308 shares. Natera maintains strong competitiveness in non-invasive genetic testing (ctDNA). ARK's relatively limited reduction may merely represent a minor adjustment to capital distribution within the precision medicine sector.

$CareDx (CDNA.US)$ Reduced holdings by 18,022 shares. CareDx focuses on post-transplant monitoring and management. ARK's slight reduction may be a routine portfolio rebalancing, with capital potentially shifting toward other healthcare innovation targets.

$Brera Holdings (SLMT.US)$ Sold 8,142 shares. Brera Holdings is relatively small in size, and this reduction was also modest, likely representing ARK's routine cleanup of non-core, small positions.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

162K Views